EdisonTV | Alternative Energy | 29/09/2016
Executive Interview - Leaf Resources
Leaf Resources (ASX:LER) is accelerating the commercialisation of its Glycell technology through its JV with Claeris, which has a proven track record of developing successful, large-scale renewable production facilities. The globally significant Gycell technology produces sugars from biomass for processing to high-value bio chemicals at a much lower cost than alternative technologies. With at least two bankable feasibility studies and further additions to the project pipeline expected, Leaf has a very strong growth path for 2017.
Leaf Resources (LER.ASX) is accelerating the commercialisation of its Glycell technology through its JV with Claeris LLC.
29/09/2016 | Leaf Resources
Ceres Power is a developer of low-cost, next-generation fuel cell technology for use in decentralised energy products that reduce operating costs, lower CO2 emissions, increase efficiency and improve energy security.
01/09/2016 | Ceres Power Holdings
Ilika (AIM: IKA) accelerates the development of new materials for energy, electronics and aerospace applications through its patented, high-throughput techniques that enable functional materials to be made, characterised and tested up to 100 times faster than traditional techniques. In partnership with international, blue-chip companies it has developed a patented methodology for producing solid-state batteries that are lighter, safer, faster to charge and last longer between charges than existing lithium-ion batteries.
04/05/2016 | Ilika
Leaf Resources Limited [ASX:LER] is focused on making sustainable products from plant biomass. The company offers an advanced technology package for breaking down plant derived biomass to useful, sustainable, renewable and biodegradable products
24/11/2015 | Leaf Resources
In diesem Webcast spricht CEO Dr Tom Berger über die Vermögenslage des Unternehmens, die Wachstumsstrategie, Wettbewerbsvorteile und die Finanzierung. Er befasst sich mit KTG‘s Positionierung in Bezug auf die Regulierung und die Biogas-Einspeisevergütungen speziell. Er erlaeutert auch die Wettbewerbsvorteile des Unternehmens durch ihre Beziehung mit Mutter KTG Agrar als auch die günstige Positionierung in Bezug auf die Diskussion "Energie statt Ernaehrung". Dr Berger erlaeutert weiter das künftige Wachstum innerhalb der Unternehmens-Strategie, wie das Wachstum finanziert werden kann, und die Dividendenpolitik.
27/05/2015 | KTG Energie
In this webcast, CEO Dr Tom Berger talks about the company’s asset position, growth strategy, competitive advantages and financing. He addresses KTG’s positioning with regards to regulation and specifically biogas feed-in tariffs. He also discusses the company’s competitive advantages through its relationship with parent KTG Agrar as well as its favourable position with regards to the energy versus food debate. Dr Berger further explains the company’s future growth strategy, how growth will be financed and the dividend policy.
27/05/2015 | KTG Energie
Albioma is an independent energy producer active in the thermal (biomass/coal), solar and anaerobic digestion power-generation sectors. The thermal generation business is the largest of Albioma’s three operating divisions in terms of installed capacity, output, revenue generation and profits, with the majority of the capacity located in the overseas departments of Reunion, Guadeloupe and Martinique. The proposed investment plan, designed to expand the business in areas of core expertise, should lead to an acceleration of growth beyond 2014.
29/11/2013 | Albioma
Global Bioenergies (GBE) is developing unique biological processes for converting renewable feedstocks into hydrocarbons, which can then be produced on an industrial scale. As well as the recent €23m capital increase, it will receive €4m from French state sources from a €5.2m package in alliance with Arkema and the Centre National de la Recherche Scientifique (CNRS). The capital increase will cover the remaining €3.3m for the first pilot, plus the estimated €15m capex requirement for the second pilot, as well as enabling further progress with its butadiene and propylene processes and the start of further new programmes. Management is currently exploring prospective sites and industrial partners for the second pilot, with more details expected to be announced in H114.
25/11/2013 | Global Bioenergies
2012 was a year of significant milestones for Oxford Catalysts, with a £30m placing plus two significant commercial milestones announced with Calumet in the US and Solena/British Airways in the UK. This culminated in Oxford Catalysts’ share price increasing 197% over the past year, making it the second best performing stock in the AIM50. See CEO Roy Lipski talk about their plans for 2013, a year that promises additional milestones for the group.
05/04/2013 | Velocys